Browse CASR

Summary
SymbolCASR
Namecalcium-sensing receptor
Aliases FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ......
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein
Domain PF00003 7 transmembrane sweet-taste receptor of 3 GCPR
PF01094 Receptor family ligand binding region
PF07562 Nine Cysteines Domain of family 3 GPCR
Function

G-protein-coupled receptor that senses changes in the extracellular concentration of calcium ions and plays a key role in maintaining calcium homeostasis (PubMed:7759551, PubMed:8702647, PubMed:8636323, PubMed:8878438, PubMed:17555508, PubMed:19789209, PubMed:21566075, PubMed:22114145, PubMed:23966241, PubMed:25292184, PubMed:25104082, PubMed:26386835, PubMed:25766501, PubMed:22789683). Senses fluctuations in the circulating calcium concentration and modulates the production of parathyroid hormone (PTH) in parathyroid glands (By similarity). The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system (PubMed:7759551). The G-protein-coupled receptor activity is activated by a co-agonist mechanism: aromatic amino acids, such as Trp or Phe, act concertedly with divalent cations, such as calcium or magnesium, to achieve full receptor activation (PubMed:27434672, PubMed:27386547).

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0005513 detection of calcium ion
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0007635 chemosensory behavior
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0044708 single-organism behavior
GO:0051592 response to calcium ion
GO:0055074 calcium ion homeostasis
GO:0070509 calcium ion import
GO:0070838 divalent metal ion transport
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
Molecular Function GO:0004435 phosphatidylinositol phospholipase C activity
GO:0004620 phospholipase activity
GO:0004629 phospholipase C activity
GO:0008081 phosphoric diester hydrolase activity
GO:0016298 lipase activity
GO:0042578 phosphoric ester hydrolase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04621 NOD-like receptor signaling pathway
Reactome R-HSA-420499: Class C/3 (Metabotropic glutamate/pheromone receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-416476: G alpha (q) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolCASR
Namecalcium-sensing receptor
Aliases FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ......
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CASR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCASR
Namecalcium-sensing receptor
Aliases FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ......
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CASR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCASR
Namecalcium-sensing receptor
Aliases FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ......
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CASR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.270.773
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.220.878
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8720.564
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1770.705
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.040.953
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.9980.0107
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CASR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277318.512.36.20.518
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275918.513.64.90.535
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.817.66.20.709
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.127.3-4.21
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382715.83.712.10.224
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161418.8018.80.228
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCASR
Namecalcium-sensing receptor
Aliases FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ......
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CASR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCASR
Namecalcium-sensing receptor
Aliases FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ......
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CASR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CASR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCASR
Namecalcium-sensing receptor
Aliases FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ......
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CASR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCASR
Namecalcium-sensing receptor
Aliases FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ......
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CASR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCASR
Namecalcium-sensing receptor
Aliases FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ......
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CASR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCASR
Namecalcium-sensing receptor
Aliases FHH; NSHPT; GPRC2A; severe neonatal hyperparathyroidism; HHC; HHC1; hypocalciuric hypercalcemia 1; EIG8; FIH ......
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CASR collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CASR.
ID Name Drug Type Targets #Targets
DB00127SpermineSmall MoleculeADRB1, ADRB2, CASR, ODC1, SMOX, SMS6
DB00994NeomycinSmall MoleculeCASR1
DB01012CinacalcetSmall MoleculeCASR1
DB05255RonacaleretSmall MoleculeADGRF1, CASR2
DB05695NPS-2143Small MoleculeCASR1
DB11093Calcium CitrateSmall MoleculeCADPS, CADPS2, CALB2, CALR, CALR3, CANX, CAPS, CASQ1, CASQ2, CASR, ......29
DB11348Calcium PhosphateSmall MoleculeCADPS, CADPS2, CALB2, CALR, CALR3, CANX, CAPS, CASQ1, CASQ2, CASR, ......29
DB12865EtelcalcetideSmall MoleculeCASR1